🚀 VC round data is live in beta, check it out!
China TCM Valuation Multiples
Discover revenue and EBITDA valuation multiples for China TCM and similar public comparables like ORIC Pharmaceuticals, EyePoint, Daewoong Pharmaceutical, Uniphar and more.
China TCM Overview
About China TCM
China Traditional Chinese Medicine Holdings Co Ltd is engaged in the Chinese healthcare sector. The company functions through four segments: Yi Fang, Tian Jiang, Tong Ji Tang, and Medi-World. It generates maximum revenue from the Yifang segment which mainly engages in the manufacture and sales of concentrated TCM granules (CTCMG), TCM healthcare products, and TCM decoction pieces under the Yi Fang brand. The majority of the revenue of the Yi Fang segment is derived from the sales of CTCMG. Geographically, it derives a majority of its revenue from Mainland China, and also has its presence in Hong Kong and Other countries.
Founded
1992
HQ
Employees
16.8K
Website
Sectors
Financials (LTM)
EV
$797M
China TCM Financials
China TCM reported last 12-month revenue of $2B and EBITDA of $177M.
In the same LTM period, China TCM generated $1B in gross profit, $177M in EBITDA, and had net loss of ($16M).
Revenue (LTM)
China TCM P&L
In the most recent fiscal year, China TCM reported revenue of $2B and EBITDA of $224M.
China TCM expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2B | XXX | $2B | XXX | XXX | XXX |
| Gross Profit | $1B | XXX | $1B | XXX | XXX | XXX |
| Gross Margin | 48% | XXX | 48% | XXX | XXX | XXX |
| EBITDA | $177M | XXX | $224M | XXX | XXX | XXX |
| EBITDA Margin | 8% | XXX | 9% | XXX | XXX | XXX |
| EBIT Margin | 1% | XXX | 6% | XXX | XXX | XXX |
| Net Profit | ($16M) | XXX | $8M | XXX | XXX | XXX |
| Net Margin | (1%) | XXX | 0% | XXX | XXX | XXX |
| Net Debt | — | — | $7M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
China TCM Stock Performance
China TCM has current market cap of $1B, and enterprise value of $797M.
Market Cap Evolution
China TCM's stock price is $0.23.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $797M | $1B | -1.6% | XXX | XXX | XXX | $0.00 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialChina TCM Valuation Multiples
China TCM trades at 0.4x EV/Revenue multiple, and 4.5x EV/EBITDA.
EV / Revenue (LTM)
China TCM Financial Valuation Multiples
As of April 10, 2026, China TCM has market cap of $1B and EV of $797M.
Equity research analysts estimate China TCM's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
China TCM has a P/E ratio of (73.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $797M | XXX | $797M | XXX | XXX | XXX |
| EV/Revenue | 0.4x | XXX | 0.3x | XXX | XXX | XXX |
| EV/EBITDA | 4.5x | XXX | 3.6x | XXX | XXX | XXX |
| EV/EBIT | 35.8x | XXX | 5.9x | XXX | XXX | XXX |
| EV/Gross Profit | 0.8x | XXX | 0.7x | XXX | XXX | XXX |
| P/E | (73.2x) | XXX | 147.8x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 2.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified China TCM Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
China TCM Margins & Growth Rates
China TCM's revenue in the last 12 month grew by 0%.
China TCM's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
China TCM's rule of 40 is 11% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
China TCM's rule of X is 9% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
China TCM Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 0% | XXX | (12%) | XXX | XXX | XXX |
| EBITDA Margin | 8% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Growth | 48% | XXX | (33%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 11% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 9% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 34% | XXX | 33% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 7% | XXX | 6% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 4% | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 42% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
China TCM Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| ORIC Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| EyePoint | XXX | XXX | XXX | XXX | XXX | XXX |
| Daewoong Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Uniphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Concord Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
China TCM M&A Activity
China TCM acquired XXX companies to date.
Last acquisition by China TCM was on XXXXXXXX, XXXXX. China TCM acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by China TCM
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialChina TCM Investment Activity
China TCM invested in XXX companies to date.
China TCM made its latest investment on XXXXXXXX, XXXXX. China TCM invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by China TCM
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout China TCM
| When was China TCM founded? | China TCM was founded in 1992. |
| Where is China TCM headquartered? | China TCM is headquartered in China. |
| How many employees does China TCM have? | As of today, China TCM has over 16K employees. |
| Is China TCM publicly listed? | Yes, China TCM is a public company listed on HKEX. |
| What is the stock symbol of China TCM? | China TCM trades under 00570 ticker. |
| When did China TCM go public? | China TCM went public in 1993. |
| Who are competitors of China TCM? | China TCM main competitors are ORIC Pharmaceuticals, EyePoint, Daewoong Pharmaceutical, Uniphar. |
| What is the current market cap of China TCM? | China TCM's current market cap is $1B. |
| What is the current revenue of China TCM? | China TCM's last 12 months revenue is $2B. |
| What is the current revenue growth of China TCM? | China TCM revenue growth (NTM/LTM) is 0%. |
| What is the current EV/Revenue multiple of China TCM? | Current revenue multiple of China TCM is 0.4x. |
| Is China TCM profitable? | Yes, China TCM is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of China TCM? | China TCM's last 12 months EBITDA is $177M. |
| What is China TCM's EBITDA margin? | China TCM's last 12 months EBITDA margin is 8%. |
| What is the current EV/EBITDA multiple of China TCM? | Current EBITDA multiple of China TCM is 4.5x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.